Heart Failure Reviews

Titel Veröffentlichungsdatum Sprache Zitate
Regulation of Matrix Metalloproteinases by Cytokines and Reactive Oxygen/Nitrogen Species in the Myocardium2004/01/01English4
Matrix Metalloproteinase Inhibitor Development and the Remodeling of Drug Discovery2004/01/01English1
The Dynamic Interaction Between Matrix Metalloproteinase Activity and Adverse Myocardial Remodeling2004/01/01English1
B-Type Natriuretic Peptide and the Right Heart2004/04/01English1
Beta Blockers as Anti-Arrhythmic Agents2004/04/01English
Editorial2004/04/01English
Pharmacokinetics and Pharmacodynamics of Beta Blockers in Heart Failure2004/04/01English
Beta-Blockers in Heart Failure: Are Pharmacological Differences Clinically Important?2004/04/01English
Beta Blocker Therapy After Acute Myocardial Infarction in Patients with Heart Failure and Systolic Dysfunction2004/04/01English
Beta Blocker Therapy in African American Patients with Heart Failure2004/04/01English
Biologic Rationale for the Use of Beta-Blockers in the Treatment of Heart Failure2004/04/01English
Sex-Related Differences in Heart Failure and Beta-Blockers2004/04/01English
The Effects of Beta Blockers on Morbidity and Mortality in Heart Failure2004/04/01English
Myocardial Remodeling in Viral Heart Disease: Possible Interactions Between Inflammatory Mediators and MMP-TIMP System2004/01/01English
Introduction to Special Issue on The Matrix Metalloproteinases: New Insights into Myocardial Remodeling2004/01/01English
Announcement: 4th World Congress on Heart Disease, Vancouver, B.C., Canada2004/01/01English
Matrix Metalloproteinases: Pathways of Induction by Bioactive Molecules2004/01/01English
MMP Induction and Inhibition in Myocardial Infarction2004/01/01English